Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma

被引：1
|
作者：
Ozaki, Kai [1 ]
Hatakeyama, Shingo [2 ]
Hamaya, Tomoko [1 ]
Okita, Kazutaka [1 ]
Hashimoto, Yasuhiro [1 ]
Ohyama, Chikara [1 ,2 ]
机构：
[1] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan
[2] Hirosaki Univ, Grad Sch Med, Dept Adv Blood Purificat Therapy, Hirosaki, Aomori, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2022年 / 29卷 / 04期
基金：
日本学术振兴会;
关键词：
D O I：
10.1111/iju.14778
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：362 / 364
页数：3
相关论文
共 50 条
  • [1] Editorial Comment to Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma
    Miyake, Makito
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (04) : 364 - 365
  • [2] CROSS-REACTIVITY BETWEEN THE FIRST-LINE CHEMOTHERAPY AND SUBSEQUENT IMMUNOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA
    Hamaya, Tomoko
    Hatakeyama, Shingo
    Ozaki, Kai
    Okita, Kazutaka
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1017 - E1017
  • [3] Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
    Tural, Deniz
    Selcukbiricik, Fatih
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Erman, Mustafa
    Coskun, Hasan Senol
    Artac, Mehmet
    Kilickap, Saadettin
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (03) : 585 - 591
  • [4] First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
    Naito, Renato
    Izumi, Kouji
    Mizokami, Atsushi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (03) : 986 - 990
  • [5] Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort
    Miyake, Makito
    Nishimura, Nobutaka
    Oda, Yuki
    Miyamoto, Tatsuki
    Iida, Kota
    Inoue, Kuniaki
    Tachibana, Akira
    Yoshikawa, Takanosuke
    Sakamoto, Keichi
    Ohnishi, Mikiko
    Maesaka, Fumisato
    Takamatsu, Norimi
    Mieda, Kosuke
    Ohmori, Chihiro
    Matsubara, Toshihiko
    Tomizawa, Mitsuru
    Shimizu, Takuto
    Ohnishi, Kenta
    Hori, Shunta
    Morizawa, Yosuke
    Gotoh, Daisuke
    Nakai, Yasushi
    Torimoto, Kazumasa
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (09) : 1311 - 1325
  • [6] Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
    Tural, Deniz
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Artac, Mehmet
    Ozhan, Nail
    Akar, Emre
    Cakar, Burcu
    Kostek, Osman
    Ekenel, Meltem
    Coskun, Hasan Senol
    Selcukbiricik, Fatih
    Keskin, Ozge
    Turkoz, Fatma Paksoy
    Oruc, Kerem
    Bayram, Selami
    Yilmaz, Ugur
    Bilgetekin, Irem
    Yildiz, Birol
    Sendur, Mehmet Ali Nahit
    Erman, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [7] Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma
    Lin, Jingwen
    Song, Xiaobing
    Fu, Wu
    You, Caicong
    Li, Na
    Liu, Maobai
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [8] Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Hong, Joohyun
    Sung, Hyun Hwan
    Jeong, Byong Chang
    Park, Se Hoon
    BIOMEDICINES, 2022, 10 (08)
  • [9] Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
    Deniz Tural
    Fatih Selçukbiricik
    Ömer Fatih Ölmez
    Ahmet Taner Sümbül
    Mustafa Erman
    Hasan Şenol Coşkun
    Mehmet Artaç
    Saadettin Kılıçkap
    International Journal of Clinical Oncology, 2022, 27 : 585 - 591
  • [10] Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first-line treatment of unresectable thymic carcinoma: A multicenter retrospective study
    Zhang, Baishen
    Liu, Yao
    Chen, Zhiting
    Chen, Jing
    Yu, Hui
    Li, Meichen
    Ma, Shudong
    Cheng, Chao
    Chen, Likun
    INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (04) : 710 - 718
12345